Chains of evidence, mosaics of data: does estrogen ‘cause’ breast cancer? How would we know?

References

• Koch R. Ueber den augenblicklichen Stand der bakteriologischen Choleradiagnose. J Hyg Inf 1893;14:319–33
   Google Scholar
• Susser M. What is a cause and how do we know one? A grammar for pragmatic epidemiology. Am J Epidemiol 1991;133: 635–48
   PubMed Web of Science ®Google Scholar
• Charlton BG. Second thoughts: Attribution of causation in epidemiology: Chain or mosaic? J Clin Epidemiol 1996;49:105–7
   PubMed Web of Science ®Google Scholar
• Hill AB. Environment and disease: association or causation? Proc R Soc Med 1965;58:295–300
   PubMed Web of Science ®Google Scholar
• Schlessman JJ, Stadel BV, Murray P, . Consistency and plausibility in epidemiologic analysis: application to breast cancer in relation to use of oral contraceptives. J Chron Dis 1987;40:1033–9
   PubMedGoogle Scholar
• Sasco AJ, Merrill RM, Dari I, . A case-control study of lung cancer in Casablanca, Morocco. Cancer Causes Control 2002;12:609–16
   Web of Science ®Google Scholar
• Taubes G. Epidemiology faces its limits. The search for subtle links between diet, lifestyle, or environmental factors and disease is an unending source of fear, but often yields little certainty. Science 1995;269:164–9
   PubMed Web of Science ®Google Scholar
• Bluming AZ. Hormone replacement therapy: benefits and risks for the general postmenopausal female population and for women with a history of previously treated breast cancer. Semin Oncol 1993;20:662–74
   PubMed Web of Science ®Google Scholar
• Bluming AZ, Tavris C. Hormone replacement therapy: real concerns and false alarms. Cancer J 2009;15:93–104
   PubMed Web of Science ®Google Scholar
• Henderson IC. Risk factors for breast cancer development. Cancer 1993;71:2127–40
   PubMed Web of Science ®Google Scholar
• Madigan M, Ziegler R, Benichou C, . Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995;87:1681–5
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300
   PubMed Web of Science ®Google Scholar
• Colditz GA, Hankinson SE, Hunter DJ, . The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589–93
   PubMed Web of Science ®Google Scholar
• Shapiro S. Risk of estrogen plus progestin therapy: a sensitivity analysis of the findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003;6:302–10
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Roussow JE, . Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103–15
   PubMed Web of Science ®Google Scholar
• www.aacr.org/home/public--media/aacr-press-releases.aspx? d =2218
   Google Scholar
• Anderson GL, Chlebowski RT, Aragaki AK, . Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomized placebo-controlled trial. Lancet 2012 March 6. Epub ahead of print
   Web of Science ®Google Scholar
• Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gyecol 2001;98: 498–508
   PubMed Web of Science ®Google Scholar
• Willis DB, Calle EE, Miracle-McMahill HL, Heath CS Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996;7:449–57
   PubMed Web of Science ®Google Scholar
• Kaufman DW, Miller DR, Rosenberg L, . Noncontraceptive estrogen use and the risk of breast cancer. JAMA 1984; 252:63–7
   PubMed Web of Science ®Google Scholar
• Stanford JL, Weiss NS, Voigt LF, . Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137–42
   PubMed Web of Science ®Google Scholar
• Hoover R. Hormones and breast cancer: etiology vs. ideology. May 15, 2007. http://videocast.nih.gov/Summary.asp? File =13823
   Google Scholar
• Charlton BG. Statistical malpractice. JR Col Phys London 1996; 30:112–14
   PubMed Web of Science ®Google Scholar
• Smith GD. Data dredging, bias, or confounding. BMJ 2002; 325:1437–8
   PubMed Web of Science ®Google Scholar
• Lagakos SW. The challenge of subgroup analyses – reporting without distorting. N Engl J Med 2006;354:1667–9
   PubMed Web of Science ®Google Scholar
• Taubes G. Do we really know what makes us healthy? Much of what we're told is based on epidemiologic studies. What if it is just bad science? NY Times Sunday Magazine Section. Sept 16, 2007;52–59, 74, 78, 80
   Google Scholar
• Barrett-Connor E. Treatment of estrogen deficiency symptoms in women surviving breast cancer. 3. Prevention of osteoporosis and CV effects of estrogens and antiestrogens. Oncology 1999;13: 397–432
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Cronin KA, Howlander N, . The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670–4
   PubMed Web of Science ®Google Scholar
• Workshop report from the Division of Cancer Etiology, National Cancer Institute. National Institutes of Health: Current perspectives and future trends in hormonal carcinogenesis. Cancer Res 1991;51:3626–9
   PubMed Web of Science ®Google Scholar
• Rosenthal ET. HRT and breast cancer epidemiological study: more definitive answers by year's end, says Peter Ravdin. Oncology Times 02/10/07, p. 17
   Google Scholar
• Ravdin P. A sharp decrease in breast cancer incidence in the United States in 2003. 29th Annual San Antonio Breast Cancer Symposium; December 14, 2006; San Antonio, TX, Abstr 5
   Google Scholar
• Ravdin PM, Cronin KA, Chlebowski RT. A decline in breast cancer incidence. N Engl J Med 2007;357:513
   Web of Science ®Google Scholar
• Decline in breast cancer cases likely linked to reduced use of hormone replacement. Science Daily, December 15, 2006
   Google Scholar
• Bluming AZ. A decline in breast cancer incidence. N Engl J Med 2007;357:509
   PubMed Web of Science ®Google Scholar
• Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003;21:28–34
   PubMed Web of Science ®Google Scholar
• Decline in breast cancer incidence – United States, 1999–2003. MMWY 2007;56:549–53
   Google Scholar
• Pickle LW, Hao Y, Jemal A, . A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin 2007;57:30–42
   PubMed Web of Science ®Google Scholar
• Glass AG, Lacey JV Jr, Carreon D, Hoover RN. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152–61
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, . for the WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57
   PubMed Web of Science ®Google Scholar
• Haddow A, Watkinson JM, Paterson E. Influence of synthetic oestrogens upon advanced malignant disease. BMJ 1944;2:393–8
   PubMedGoogle Scholar
• Massida B, Mascia V, Broccia G, . Estrogen therapy of advanced breast cancer. Minerva Med 1977;68:2509–16
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Hug V, Buzdar AU, . Sequential cyclic combined hormonal therapy for metastatic breast cancer. Cancer 1989;64:1002–6
   PubMed Web of Science ®Google Scholar
• Ingle J, Ahmann D, Green S, . Randomized clinical trial of diethylstilbestrol vs tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981;304:16–21
   PubMed Web of Science ®Google Scholar
• Peethambaram P, Ingle J, Suman V, . Randomized clinical trial of diethylstilbestrol vs tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 1999;54:117–22
   PubMed Web of Science ®Google Scholar
• Lonning PE, Taylor PD, Anker G, . High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001;67:111–16
   PubMed Web of Science ®Google Scholar
• Mahtani RL, Stein A, Vogel CL. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: A restrospective chart review. Clin Therap 2009;31:2371–8
   PubMed Web of Science ®Google Scholar
• Craig-Jordan V, Lewis-Wambi J, Kim H, . Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. Breast 2007;16(Suppl 2):105–13
   Web of Science ®Google Scholar
• Feynman R. The meaning of it all: thoughts of a citizen-scientist. From a series of three lectures in April, 1963 at University of Washington, Seattle as part of the John Danz Lecture Series. Reading, Massachusetts: Helix Books, Addison Wesley, 1998:171
   Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, . Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, . for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243–53
   PubMed Web of Science ®Google Scholar
• Santen RJ, Pinkerton J, McCartney C, . Risk of breast cancer with progestins in combination with estrogen as HRT. J Clin Endocrinol Metab 2001;86:16–23
   PubMed Web of Science ®Google Scholar
• Gorins A. Progestins and risk of breast cancer. Much ado about nothing? Eur J Gynaecol Oncol 2003;24:345–50
   PubMed Web of Science ®Google Scholar
• Van Veelen H, Willemse PHB, Tjabbes T, . Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer 1986;58:7–13
   PubMed Web of Science ®Google Scholar
• Hrushesky WJM, Bluming AZ, Gruber SA, . Menstrual influence on surgical cure of breast cancer. Lancet 1989;2:949–52
   PubMed Web of Science ®Google Scholar
• Bluming A, Hrushesky WJM. The effect of surgical timing within the fertility cycle on breast cancer outcome. Ann NY Acad Sci 1991;618:277–91
   PubMed Web of Science ®Google Scholar
• Badwe RA, Gregory WM, Chaudary MA, . Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 1991;337:1261–4
   PubMed Web of Science ®Google Scholar
• Senie RT, Rosen PP, Rhodes P, Lesser ML. Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Ann Intern Med 1991;115:337–42
   PubMed Web of Science ®Google Scholar
• Spratt JS, Zirnheld J, Yancey JM. Breast Cancer Detection Demonstration Project data can determine whether the prognosis of breast cancer is affected by time of surgery during the menstrual cycle. J Surg Oncol 1993;53:4–9
   PubMed Web of Science ®Google Scholar
• Veronesi U, Luini A, Mariani L, . Effect of menstrual phase on surgical treatment of breast cancer. Lancet 1994;343:1545–7
   PubMed Web of Science ®Google Scholar
• Saad Z, Branwell V, Duff J, . Timing of surgery in relation to the menstrual cycle in premenopausal women with operable breast cancer. Br J Surg 1994;81:217–20
   PubMed Web of Science ®Google Scholar
• Holli K, Isola J, Hakama M. Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient: fact or fallacy. Br J Cancer 1995;71:124–7
   PubMed Web of Science ®Google Scholar
• Harlap S, Zauber AG, Pollack DM, . Survival of premenopausal women with breast carcinoma. Effects of menstrual timing of surgery. Cancer 1998;83:76–88
   PubMed Web of Science ®Google Scholar
• Powles TJ, Jones AL, Ashley S, . Menstrual effect on surgical cure of breast cancer. Lancet 1989;2:1343–4
   Web of Science ®Google Scholar
• Gelber RD, Goldhirsch A. Menstrual effect on surgical cure of breast cancer. Lancet 1989;2:1344
   Google Scholar
• Rageth JC, Wyss P, Unger C, . Timing of breast cancer surgery within the menstrual cycle: influence on lymph-node involvement, receptor status, postoperative metastatic spread and local recurrence. Ann Oncol 1991;2:269–72
   PubMed Web of Science ®Google Scholar
• Gnant MFX, Seifert M, Jakesz R, . Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 385 pre-menopausal women. Int J Cancer 1992;52:707–12
   PubMed Web of Science ®Google Scholar
• Kroman N, Hojgaard A, Andersen KW, . Timing of surgery in relation to menstrual cycle does not predict the prognosis in primary breast cancer. Danish Breast Cancer Cooperative Group. Eur J Surg Oncol 1994;20:430–5
   PubMedGoogle Scholar
• Jager W, Sauerbrei W. Effect of timing of surgery during the menstrual cycle of premenopausal breast cancer patients. Br Cancer Res Treat 1995;34:279–87
   PubMed Web of Science ®Google Scholar
• Grant CS, Ingle JN, Suman VJ, . Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 Study. J Clin Oncol 2009;27:3620–6
   PubMed Web of Science ®Google Scholar
• Sainsbury R, Perren TJ, Brown SR, . Does timing of breast cancer surgery in relation to menstrual cycle phase affect prognosis: The Yorkshire Breast Cancer Group Intervention, Timing and Survival Study. J Clin Oncol 2005;23(16S):536
   Web of Science ®Google Scholar
• Badwe RA, Wang DY, Gregory WM, . Serum progesterone at the time of surgery and survival in women and premenopausal operable breast cancer. Eur J Cancer 1994;30A: 445–8
   PubMed Web of Science ®Google Scholar
• Mohr PE, Wang DY, Gregory WM, . Serum progesterone and prognosis in operable breast cancer. Br J Cancer 1996; 73:1552–5
   PubMed Web of Science ®Google Scholar
• Senie RT, Tenser SM. The timing of breast cancer surgery during the menstrual cycle. Oncology 1997;11:1509–17
   PubMedGoogle Scholar
• Badwe R, Hawalder R, Parmar V, . Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. J Clin Oncol 2011;29:2845–51
   PubMed Web of Science ®Google Scholar
• Mukherjee S. The Emperor of all Maladies: A Biography of Cancer. New York: Scribner, 2010:266
   Google Scholar
• Thun MJ Hannan LM, Adams-Campbell LL, . Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 2008;5:e185
   PubMed Web of Science ®Google Scholar
• Fletcher AS, Erbas B, Kavanagh AM, . Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis. Breast 2005;14:192–200
   PubMed Web of Science ®Google Scholar
• Heiss G, Wallace R, Anderson GL, . for the WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036–45
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Gass M, . for the WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684–92
   PubMed Web of Science ®Google Scholar